Neurocrine Biosciences (NBIX) CLO Lippoldt Buys $799K of Stock
Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, bought 9,800 shares as the company continues to attract analyst attention.
Reviewed by automated data checks against the source filing. How we make and check alerts
Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, Inc. ($NBIX), bought 9,800 shares at an average price of $81.49, worth about $798,602, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NBIX is up 2.4% after 1 week, up 6.3% after 1 month and down 20.2% to date (from the $170 close on Jun 29, 2026).
NBIX
Neurocrine Biosciences, Inc.
Key Points
- Darin Lippoldt purchased 9,800 shares of Neurocrine Biosciences for about $798,602 on June 29, 2026, at an average price of $81.49.
- The stock was trading at $168.54 on Wednesday, indicating a significant premium compared to the purchase price.
- Analyst ratings remain strong, with a consensus of 'strong buy' and a mean price target of $208.40.
Get $NBIX trade alerts by text
We text you when insiders, Congress or big funds trade $NBIX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Neurocrine Biosciences, Inc. alert may contain errors. Disclosures
Lippoldt's Large Purchase
Darin Lippoldt, the Chief Legal Officer at Neurocrine Biosciences, Inc. (NASDAQ: NBIX), bought 9,800 shares for about $798,602 on June 29, 2026. He paid an average of $81.49 per share. This move reflects confidence in the company as it continues to expand its pharmaceutical offerings.
What's New with Lippoldt's Position
This transaction adds to Lippoldt's holdings, which includes previous purchases made just days before. On June 26, 2026, he bought 400 shares at the same price of $81.49 each, totaling approximately $32,596. Now, after the latest buy, his position has grown significantly, and his total holdings in Neurocrine are likely around 10,200 shares.
Analysts Set New Price Targets
Neurocrine is getting positive feedback from analysts. Needham recently reiterated a 'Buy' rating with a target price of $204. On the other hand, BMO Capital maintained a 'Market Perform' rating but adjusted its target down to $150 from $164. Overall, the consensus is a 'strong buy', with a mean target price of approximately $208.40, indicating confidence in future stock performance.
Stock Performance Context
As of the publication date on Wednesday, June 29, 2026, Neurocrine's stock was trading at $168.54. This price is notably above the 52-week low of $122.14 and well below the 52-week high of $186.12, suggesting it is in a strong position relative to its recent trading history.
Recent Earnings
Neurocrine's latest financials show revenue of $3.37 billion with a growth rate of 39.5%. The company has an earnings per share (EPS) of $6.84 and a net margin of about 20.9%. It plans to report its next earnings on October 28, 2026, which may give more insight into its performance and strategy.
Insight into Neurocrine
Neurocrine Biosciences focuses on developing treatments for neurological and psychiatric conditions. Its portfolio includes medications for disorders like tardive dyskinesia and endometriosis, and it continues to innovate with new drug candidates in the pipeline, making insider purchases noteworthy for shareholders.
What's Ahead for Neurocrine Biosciences, Inc.
With Darin Lippoldt's recent significant purchase and ongoing analyst support, attention will now turn to the upcoming earnings report on October 28, 2026. This will help clarify the company's performance and might influence future trading decisions. It's essential to remember that Lippoldt's trades reflect past actions and may not represent his current holdings.
Related Filing Alerts
Source: Darin Lippoldt's Form 4 filing on $NBIX (Jun 29, 2026). Find the original filing: NBIX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts